Posted by Michael Wonder on 30 Mar 2025
FDA issues complete response letter for etripamil for PSVT
28 March 2025 - Complete response letter focused on CMC; no clinical issues relating to etripamil raised.
Milestone Pharmaceuticals today announced the US FDA issued a complete response letter regarding its new drug application for Cardamyst (etripamil) nasal spray, a prescription medication in development for the conversion of acute episodes of PSVT to sinus rhythm in adults.
